These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31271060)

  • 1. The differential effect of clarithromycin and azithromycin on induction of macrolide resistance in
    Schildkraut JA; Pennings LJ; Ruth MM; de Brouwer AP; Wertheim HF; Hoefsloot W; de Jong A; van Ingen J
    Future Microbiol; 2019 Jun; 14():749-755. PubMed ID: 31271060
    [No Abstract]   [Full Text] [Related]  

  • 2. Dissecting
    Richard M; Gutiérrez AV; Kremer L
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31791943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus.
    Maurer FP; Castelberg C; Quiblier C; Böttger EC; Somoskövi A
    J Antimicrob Chemother; 2014 Jun; 69(6):1559-63. PubMed ID: 24500188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of drug-susceptibility patterns and gene sequences associated with clarithromycin and azithromycin resistance in
    Yoshida S; Tsuyuguchi K; Kobayashi T; Inoue Y; Suzuki K
    J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33570485
    [No Abstract]   [Full Text] [Related]  

  • 5. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance.
    Choi GE; Shin SJ; Won CJ; Min KN; Oh T; Hahn MY; Lee K; Lee SH; Daley CL; Kim S; Jeong BH; Jeon K; Koh WJ
    Am J Respir Crit Care Med; 2012 Nov; 186(9):917-25. PubMed ID: 22878281
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Cheng A; Tsai YT; Chang SY; Sun HY; Wu UI; Sheng WH; Chen YC; Chang SC
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs.
    Brown-Elliott BA; Vasireddy S; Vasireddy R; Iakhiaeva E; Howard ST; Nash K; Parodi N; Strong A; Gee M; Smith T; Wallace RJ
    J Clin Microbiol; 2015 Apr; 53(4):1211-5. PubMed ID: 25653399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A real-time PCR assay for rapid identification of inducible and acquired clarithromycin resistance in Mycobacterium abscessus.
    Sharma MK; La Y; Janella D; Soualhine H
    BMC Infect Dis; 2020 Dec; 20(1):944. PubMed ID: 33302900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study.
    Malhotra-Kumar S; Lammens C; Coenen S; Van Herck K; Goossens H
    Lancet; 2007 Feb; 369(9560):482-90. PubMed ID: 17292768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the
    Pryjma M; Burian J; Kuchinski K; Thompson CJ
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.
    Nash KA; Brown-Elliott BA; Wallace RJ
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1367-76. PubMed ID: 19171799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-to-Detection of Inducible Macrolide Resistance in Mycobacterium abscessus Subspecies and Its Association with the Erm(41) Sequevar.
    Christianson S; Grierson W; Kein D; Tyler AD; Wolfe J; Sharma MK
    PLoS One; 2016; 11(8):e0158723. PubMed ID: 27490181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections.
    Jeong SH; Kim SY; Huh HJ; Ki CS; Lee NY; Kang CI; Chung DR; Peck KR; Shin SJ; Koh WJ
    Int J Infect Dis; 2017 Jul; 60():49-56. PubMed ID: 28522316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro Activity of Rifabutin and Clofazimine to Macrolide-Resistant Mycobacterium abscessus Complex Clinical Isolates].
    Sürücüoğlu S; Özkütük N; Gazi H; Çavuşoğlu C
    Mikrobiyol Bul; 2023 Oct; 57(4):639-649. PubMed ID: 37885391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing.
    Bastian S; Veziris N; Roux AL; Brossier F; Gaillard JL; Jarlier V; Cambau E
    Antimicrob Agents Chemother; 2011 Feb; 55(2):775-81. PubMed ID: 21135185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro induction of resistance by tissue concentrations of azithromycin, clarithromycin, cefixime and amoxicillin/clavulanate in clinical isolates of Streptococcus pyogenes.
    De Vecchi E; Nicola L; Zucchetti E; Drago L
    J Chemother; 2006 Aug; 18(4):379-88. PubMed ID: 17024793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance.
    Burgess DS; Hastings RW; Horan JL
    Ann Pharmacother; 1999 Dec; 33(12):1262-5. PubMed ID: 10630825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic correlates of clarithromycin susceptibility among isolates of the Mycobacterium abscessus group and the potential clinical applicability of a PCR-based analysis of erm(41).
    Carvalho NFG; Pavan F; Sato DN; Leite CQF; Arbeit RD; Chimara E
    J Antimicrob Chemother; 2018 Apr; 73(4):862-866. PubMed ID: 29272470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel DNA chromatography method to discriminate Mycobacterium abscessus subspecies and macrolide susceptibility.
    Yoshida M; Sano S; Chien JY; Fukano H; Suzuki M; Asakura T; Morimoto K; Murase Y; Miyamoto S; Kurashima A; Hasegawa N; Hsueh PR; Mitarai S; Ato M; Hoshino Y
    EBioMedicine; 2021 Feb; 64():103187. PubMed ID: 33446475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.
    Matic V; Kosowska K; Bozdogan B; Kelly LM; Smith K; Ednie LM; Lin G; Credito KL; Clark CL; McGhee P; Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4103-12. PubMed ID: 15504828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.